Vanguard Capital Wealth Advisors Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Vanguard Capital Wealth Advisors cut its stake in Pfizer Inc. (NYSE:PFE) by 14.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,805 shares of the biopharmaceutical company’s stock after selling 1,711 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Pfizer were worth $282,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.03 during midday trading on Tuesday, hitting $25.61. The company’s stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The firm’s fifty day moving average price is $26.92 and its 200-day moving average price is $28.31. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $145.02 billion, a P/E ratio of 71.50, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.56%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.